COVID-19
Conditions
Interventions
Experimental group:Azovudine+Traditional Chinese medicine
Sponsors
The Fifth Hospital of Shijiazhuang
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1)Male and female, aged 18 to 65 years; (2)Confirmed diagnosis of mild or moderate COVID-19 within 48 hours before randomization; (3)Have COVID-19 vaccination; (4)Voluntary participation and have signed the informed consent form. Can comply with the clinical trial.
Exclusion criteria
Exclusion criteria: (1)Plan to give birth within one year, or pregnant women, or lactating women; (2)Allergic to Azovudine; (3)Suspected or confirmed active systemic infection in addition to COVID-19 (4)Severe respiratory diseases such as asthma, bronchiectasis, chronic obstructive pulmonary disease, pulmonary interstitial disease, pulmonary tuberculosis and other respiratory diseasess that affect clinical trial evaluation (5)History of other serious diseases, including but not limited to malignant tumors, cardiovascular and cerebrovascular diseases, blood diseases, cachexia, active bleeding, severe malnutrition, mental diseases, autoimmune diseases, etc.; (6)Moderate and severe liver and kidney function damage, defined as ALT and/or AST exceed the upper limit of normal value by 3 times, or total bilirubin exceeds the upper limit of normal value by 2 times; creatinine exceeds the upper limit of normal value; (7)Have participated in clinical trials or intervention studies of other drugs in the past 3 months; (8)Other conditions that are not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in immunocyte;Changes in cytokine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Nucleic acid testing;Body temperature;Clinical symptoms;Pulmonary inflammation;COVID-19 classification;Hospital stay; | — |
Countries
China
Contacts
Public ContactErhei Dai
The Fifth Hospital of Shijiazhuang
Outcome results
None listed